Drug Channels

JULY 29, 2020

In this issue: Pricing problems for diabetes treatments Controversy over Regeneron’s copay support Massachusetts concedes that coupons help some patients (but accumulators hurt) A 2020 update to my all-time favorite chart Plus, thoughtful perspectives on diversity from AmerisourceBergen CEO Steve Collis.

Diabetes 52

Diabetes Biosimilars 52

pharmaphorum

JUNE 24, 2021

The original formulation has started to lose patent protection however, and a gaggle of drug developers – including Samsung Bioepis/Biogen, Hospira and Formycon/Bioeq – are already preparing to enter the US market with lower-cost biosimilars , with the first rivals expected to launch before year-end. Last year, Roche booked around $1.5

Diabetes 95

Diabetes Biosimilars Drug Development 95

pharmaphorum

AUGUST 23, 2021

Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis’ copycat drug Byooviz. Sales reached a peak in 2019, when Roche booked $1.8 billion in sales from the drug while Novartis made $2.1 billion for Roche and $1.9

Biosimilars 40

Biosimilars Diabetes 40

pharmaphorum

DECEMBER 21, 2020

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

Biosimilars 126

Biosimilars Chemotherapy Immunity Immunization 126

European Pharmaceutical Review

FEBRUARY 22, 2023

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Under the agreement, Celltrion will exclusively supply to Rani the ustekinumab biosimilar drug substance (CT-P43) required for its RT-111 programme. Diabetes Therapy. 2019 [cited 2023Feb]. Pharmaceutics.

Biosimilars 105

Biosimilars Diabetes Immunization Immunity 105

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

pharmaphorum

JUNE 1, 2021

Protection has already expired in the US – where it is sold by Roche – but biosimilars are not expected to reach the US market until the latter half of this year. $8 Beovu was intended to maintain Novartis’ wet AMD franchise once Lucentis starts to fade, and made its debut in the US in October 2019 with analysts predicting sales of $2.5

Biosimilars 66

Biosimilars Diabetes 66

pharmaphorum

MAY 21, 2021

It builds on the company’s four partnership projects: two with the generics and biosimilars firm Hikma, one with US biotech Inhibrix and another with an unnamed biosimilars partner. Eli Lilly, Novo Nordisk and there’s a group of biosimilar companies who already have a footprint in diabetes.”

Biosimilars 52

Biosimilars Diabetes 52

pharmaphorum

JANUARY 30, 2022

The US regulator has given the green light to the bispecific antibody – now called Vabysmo – for both neovascular or ‘wet’ age-related macular degeneration (AMD) and diabetic macular oedema (DME). Beovu launched in October 2019 in the US with sales predictions of $2.5 Image by analogicus from Pixabay .

Biosimilars 52

Biosimilars Diabetes 52

STAT

NOVEMBER 18, 2022

The first therapy that delays the onset of type 1 diabetes received approval from the U.S. As of 2019, about 1.9 million people have type 1 diabetes in the U.S., according to the American Diabetes Association, including 244,000 children and adolescents. Type 1 affects 8% of everyone with diabetes.

Diabetes 246

Diabetes Biosimilars Documentation Compounding 246

pharmaphorum

APRIL 13, 2022

It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone. In recent years, there have been more developments in the area of diabetes management, with the emergence of metformin and more recently semaglutide and dulaglutide.

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

Pharmaceutical Technology

MARCH 8, 2023

This is the second time Lilly has significantly reduced the cost of its insulin, as in 2019 the company reduced the list price of Humalog by 50%. This recent price reduction to $35 has significant impact as rationing of insulin dosing has led to an increasing number of deaths among diabetics.

Biosimilars 105

Biosimilars Diabetes 105

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

PharmaShots

APRIL 13, 2023

Novartis intended to separate its eye care division, Alcon, into an independent company which is expected to be completed in 2019. summing the revenue to $29.63B In the year 2019, Roche held the second position among the top 20 biopharma companies with the sales of $63.5B stake in GSK Consumer Healthcare to GSK.

Biosimilars 40

Biosimilars Vaccines Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

FEBRUARY 26, 2021

billion) hit the company in 2019. During this tenure, J&J entered into the areas of vision care, mechanical wound closure and diabetes management. In 2012, J&J agreed to pay US $181 million to 26 states in order to settle these claims – though another lawsuit related to the drug (for $8 billion, eventually reduced to $6.8

Vaccines 126

Vaccines Biosimilars Labelling Communication 126

pharmaphorum

DECEMBER 2, 2020

Others rapidly followed, including Glucotrol, aimed at diabetics, and Procardia, an anti-hypertensive. In 2015 the company also paid $17 billion to acquire Hospira , a firm specialising in injectable drugs and biosimilars, at a time when copycat biologics were starting to make real waves in the market.

Compounding 128

Compounding Vaccines Biosimilars Diabetes 128

pharmaphorum

JANUARY 5, 2021

Healthcare systems ended 2020 in a very different place to where they were in 2019, with hospital capacity (and hospital finances) challenges. The focus is likely to be on people who may have chronic, primary care treatable conditions, such as hypertension, dyslipidaemia, or early type II diabetes.

Hospitals 105

Hospitals Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

PharmaShots

APRIL 3, 2023

The system offers alternative options for those patients receiving other medications The system was originally approved in 2019 for treating chronic pain. The system offers alternative options for those patients receiving other medications The system was originally approved in 2019 for treating chronic pain. events/100 patient-yrs.)

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

RX Note

FEBRUARY 23, 2023

. - Drug registration number Medicines (Advertisement & Sale) Act 1956 and Regulations - To learn prohibitions of medicine advertisement and Medicine Advertisement Board Registration of Pharmacists Act 1951 and Regulations - Pharmacy Board Malaysia and legislation aspects of provisional, full and temporary registration Code of Ethics for Pharmacists (..)

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58